Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.
Publication/Presentation Date
12-1-2017
Abstract
Thyroid disorders have emerged as one of the most common immune-related adverse events associated with anti-PD-1 monotherapy or combination anti-PD-1 and anti-CTLA-4 therapy. This study characterizes and compares the evolution of monotherapy and combination therapy-related thyroid disorders. We analyzed the dynamic evolution of thyroid disorders in 45 patients who developed thyroid disorders following treatment with either anti-PD-1 monotherapy or anti-PD-1 and anti-CTLA-4 combination therapy. The patients presented with thyrotoxicosis or hypothyroidism as the initial presentation of their thyroid disorder. Thyrotoxicosis as the initial presentation occurred in the majority of patients (93% and 56% of the patients receiving combination therapy and monotherapy, respectively). The onset pattern of the thyroid disorder was significantly different between the two groups (
Volume
5
Issue
12
First Page
1133
Last Page
1140
ISSN
2326-6074
Published In/Presented At
Lee, H., Hodi, F. S., Giobbie-Hurder, A., Ott, P. A., Buchbinder, E. I., Haq, R., Tolaney, S., Barroso-Sousa, R., Zhang, K., Donahue, H., Davis, M., Gargano, M. E., Kelley, K. M., Carroll, R. S., Kaiser, U. B., & Min, L. (2017). Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer immunology research, 5(12), 1133–1140. https://doi.org/10.1158/2326-6066.CIR-17-0208
Disciplines
Medicine and Health Sciences
PubMedID
29079654
Department(s)
Fellows and Residents
Document Type
Article